YAPing Hippo Forecasts a New Target for Lung Cancer Prevention and Treatment

The Hippo signaling pathway is a central regulator of organ size in diverse animals from insects to mammals.1,2 Genetic perturbation of this pathway in mouse models results in massively enlarged organs accompanied by tumor formation.3-5 Given its essential role in normal growth control in animal development, one would predict that the Hippo pathway is a target of gene mutations in cancer. To date, the evidence supporting this hypothesis has been limited. In Journal of Clinical Oncology, Chen et al6 have begun to fill this knowledge gap by identifying a missense mutation in YAP (also known as YAP1 or YAP65), a key component of the Hippo pathway, as a germline risk allele for lung adenocarcinoma. The Hippo signaling pathway was initially discovered as a growth-inhibitory mechanism in the fruit fly Drosophila melanogaster, a classic model organism for developmental biologists.7,8 In Drosophila, this pathway comprises several tumor suppressor proteins, including two kinases, Hippo (Hpo) and Warts (Wts), that signal through a core kinase cascade to converge on the phosphorylation and inactivation of an oncogene called Yorkie (Yki; Fig 1). Yki functions as a transcriptional coactivator for a DNA-binding transcription factor called Scalloped to facilitate the transcription of growth-promoting genes such as cell cycle regulators and antiapoptotic proteins.9-11 Hippo-mediated phosphorylation of Yki inactivates the growth-promoting activity of Yki by excluding the phosphorylated Yki from the nucleus.3 Fig 1 The diagrams of the Hippo signaling pathway in (A) Drosophila melanogaster and (B) mammals highlight the core kinase cascade and upstream regulatory signals. For simplicity, most of the regulatory proteins upstream of the kinase cascade are not included ... The Hippo pathway is conserved in mammals wherein counterpart tumor suppressors function through a similar kinase cascade to inactivate YAP and a related protein called TAZ, which are the two mammalian counterparts of Yki3,12 (Fig 1). Recent studies suggest that the Hippo pathway is regulated by many biologic inputs such as cell polarity, adhesion and mechanical forces, and secreted ligands.13,14 Although the exact mechanisms by which these biologic inputs are modulated spatially and temporally to precisely terminate organ growth at appropriate size during development remain to be determined, it is known that developmental regulation of Hippo signaling in both Drosophila and mammals requires an upstream regulator called Merlin, a “4.1, ezrin, radixin, moesin” domain-containing adaptor protein localized to the cell cortex15-17 (Fig 1). In both Drosophila and mice, inactivation of Hippo pathway tumor suppressors, or activation of the oncogene Yki/YAP, leads to tremendous tissue hyperplasia characterized by excessive cell proliferation and diminished apoptosis, two hallmarks of cancer. Indeed, in several mouse tissues, these genetic manipulations also result in tumorigenesis.3-5 In contrast to the spectacular phenotypes in animal studies, mutations in Mstl/2 and Latsl/2, the human counterparts of Hpo and Wts, respectively, are extremely rare in human cancers. Instead, these genes were reported to be silenced by hypermethylation in certain cancers.18-20 The only tumor suppressor related to the Hippo pathway that has been consistently linked to human cancer is the upstream regulator Merlin. Merlin, also called NF2, was discovered two decades ago as a tumor suppressor gene whose mutations cause neurofibromatosis 2, an inherited autosomal dominant disorder characterized by the development of schwannomas and meningiomas affecting the nervous system.21,22 Somatic mutations of NF2 are also frequently found in mesotheliomas.23 It is not immediately clear why mutations of the core components of the Hippo pathway have not been more frequently detected in human cancers. This could simply be a matter of statistical improbability. Unlike Drosophila, humans encode two homologues of Hpo (Mstl and Mst2) and Wts (Latsl and Lats2). Thus a human cell has to encounter four instead of two hits at the relevant genetic loci to abolish Hpo or Wts activity. In contrast, NF2 is the sole Merlin homolog in humans. Although genetic redundancy may in principle account for the dearth of mutations in tumor suppressor genes of the Hippo pathway, gain-of-function mutations in the oncogenes of the pathway should not be subjected to the same constraints. Supporting this view, the YAP gene locus on human chromosome 11q22 is amplified in various tumors such as lung, pancreas, oral, esophagus, liver, and ovarian carcinomas.24-29 However, the frequency of YAP amplification in these tumors is relatively low (5% to 10%). To complicate matters further, the YAP gene locus was also reported to undergo frequent loss of heterozygosity in breast cancer.30 Indeed, although the prevailing view holds that YAP functions as a growth-promoting oncogene, YAP has also been proposed to function as a tumor suppressor gene in some contexts.30,31 Against this backdrop, the identification by Chen et al6 of an R331W missense mutation in YAP as a germline risk allele for lung adenocarcinoma is notable for several reasons. First and foremost, this information can be immensely valuable for early detection and disease prevention of lung adenocarcinoma. As beautifully illustrated by the authors, even though the R331W mutation is a rare allele, the high penetrance of mutant carriers to have lung adenocarcinoma and related lung lesions warrants the use of low-dose computed tomography scans as a preventive measure to this high-risk subpopulation.6 This practice allowed the authors to diagnose a stage I adenocarcinoma in one carrier who would otherwise become aware of the disease only at a much later stage. In addition, it provides unbiased clinical evidence that further implicate the Hippo signaling pathway as a cancer-relevant pathway. Finally, the dominant nature of the R331W mutation in increasing lung cancer risk and its gain-of-function activity in cellular assays provides further evidence supporting YAP as a bona fide oncogene and further validates the widespread interest of developing small-molecule inhibitors of YAP. Indeed, recent studies have demonstrated the proof of principle that YAP inhibitors can be successfully developed by identifying small molecules that disrupt the physical interaction between YAP and its transcription factor partner.8a Thus, YAP may be a promising and pharmacologically viable target for lung cancer prevention and treatment. Like many good studies, the work of Chen et al6 raises interesting questions that warrant further investigation. Although the authors showed that the R331W missense mutation increases the colony formation ability and invasion potential of a lung cancer cell line in culture, the precise mechanism by which the R331W mutation confers predisposition to lung cancer remains unknown. Does the mutation increase the transcriptional activity, nuclear localization, or protein abundance of YAP? It is noteworthy that two patients who had lung cancer with the R331W allele in the Chen et al6 study also had breast cancer. A more systematic survey of the R331W carriers will be required to better appreciate the tissue-specific effect, or the lack thereof, of this allele in cancer predisposition. If the R331W allele predisposes patients to only lung adenocarcinoma but not other cancers, it will be extremely interesting to investigate how this mutation has such a selective effect on lung cancer development It was shown recently that YAP plays a critical role in the self-renewal of airway stem cells.32,33 Perhaps a better understanding of how the Hippo-YAP pathway is uniquely regulated in the lung progenitor cells may provide some insights into this question. We have now come full circle, in as much as developmental biology has informed cancer biology, our understanding of cancer genome landscapes presents a rich opportunity for deeper exploration of basic developmental processes.